Equillium, Inc. (NASDAQ:EQ) Short Interest Up 31.5% in December

Equillium, Inc. (NASDAQ:EQ) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 103,600 shares, a growth of 31.5% from the December 15th total of 78,800 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average trading volume of 187,700 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Trading of Equillium

An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC increased its holdings in shares of Equillium, Inc. (NASDAQ:EQ) by 43.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 300,400 shares of the company’s stock after purchasing an additional 91,200 shares during the quarter. Renaissance Technologies LLC owned 0.85% of Equillium worth $208,000 at the end of the most recent reporting period. 27.05% of the stock is currently owned by institutional investors and hedge funds.

Equillium Trading Down 8.0 %

Equillium stock traded down $0.06 during midday trading on Friday, hitting $0.64. 120,797 shares of the stock were exchanged, compared to its average volume of 138,057. The stock has a market capitalization of $22.81 million, a price-to-earnings ratio of -4.60 and a beta of 1.78. The stock’s 50-day simple moving average is $0.71 and its 200 day simple moving average is $0.82. Equillium has a fifty-two week low of $0.56 and a fifty-two week high of $3.25.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.